Given its human atrial specificity and vital contribution to action potential formation [6], Kv1.5 is taken as a new pharmacological target for atrial fibrillation [7], [8], and thus many potent Kv1.5 inhibitors have been developed [9], such as (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide (DPO-1) [10], mephetyl tetrazole (MT) [11], AVE0118 [9], AVE1231 [12]. The gene discussed is KCNA5; the disease is atrial fibrillation.